Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company which develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Beyond Air news
29.06.2022
Beyond Air's GAAP loss for fiscal year 2022 was $44.06 million, up 92.6 percent from $22.875 million the previous year. The company earned no revenue. A year earlier, the figure was $873,000.
Source: 
beyondair.net
beyondair.net
11.02.2022
Beyond Air's GAAP loss for 9 months of fiscal year 2022 was $23.397 million, up 32.6% from $17.643 million in the previous year. The company did not generate revenue. A year earlier it was $728,000.
Source: beyondair.net
beyondair.net
12.11.2021
Beyond Air reported a GAAP loss of $15.435 million for the first six months of fiscal year 2022, up 30% from $11.874 million in the previous year. The company did not generate revenue. A year earlier it was $579,000.
Source: beyondair.net
beyondair.net
11.08.2021
Beyond Air's GAAP loss for 3M FY 2022 was $6.743 million, unchanged significantly from $6.742 million in the prior year.
Source: beyondair.net
beyondair.net
General information
| Company name | Beyond Air |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 825 EAST GATE BOULEVARD, SUITE 320 GARDEN CITY NY 11530 516-665-8200 |
| Mailing address | 825 EAST GATE BOULEVARD, SUITE 320 GARDEN CITY NY 11530 |
| Website | www.ait-pharm.com |
| Information disclosure | www.sec.gov |
English (US) 